Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Balchem ( (BCPC) ) has provided an announcement.
On December 9, 2025, Balchem Corporation’s Board of Directors declared a dividend of $0.96 per share, marking a 10.3% increase from the previous year, payable on January 20, 2026. Additionally, the Board approved a new stock repurchase program allowing the repurchase of up to 4 million shares, replacing the previous program, with no expiration date and flexible execution, reflecting confidence in the company’s long-term strategies.
The most recent analyst rating on (BCPC) stock is a Hold with a $162.00 price target. To see the full list of analyst forecasts on Balchem stock, see the BCPC Stock Forecast page.
Spark’s Take on BCPC Stock
According to Spark, TipRanks’ AI Analyst, BCPC is a Outperform.
Balchem Corporation’s overall stock score of 80 reflects its strong financial performance and positive earnings call, which highlight record-breaking growth and strategic initiatives. The technical analysis suggests potential short-term volatility, and the valuation indicates the stock may be overvalued. However, the company’s robust financial health and positive outlook support a favorable stock assessment.
To see Spark’s full report on BCPC stock, click here.
More about Balchem
Balchem Corporation develops, manufactures, and markets specialty ingredients aimed at enhancing health and well-being across various industries globally. The company operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, offering solutions for the food, supplement, pharmaceutical, animal health, and agricultural markets.
Average Trading Volume: 171,753
Technical Sentiment Signal: Hold
Current Market Cap: $4.77B
Find detailed analytics on BCPC stock on TipRanks’ Stock Analysis page.

